Table 1 Characteristics of the patients at baseline
Characteristic | Lansoprazole group (N = 109) | Esomeprazole group (N = 56) | P value |
|---|---|---|---|
Dosage-no. (%) | 15 mg; 90 (82.6) 30 mg; 19 (17.4) | 10 mg; 9 (16.1) 20 mg; 47 (83.9) | - |
Median Age (yr)-(IQR) | 71.0 (66.0–79.0) | 68.0 (63.0–76.3) | 0.209 |
Male-no. (%) | 77 (71.0) | 37 (66.1) | 0.595 |
Median BMI (kg/m2)-(IQR) | 24.3 (23.1–26.8) | 24.9 (22.1–26.3) | 0.539 |
Median GBS score- (IQR) | 2 (0–3) | 1 (0–2) | 0.292 |
Acute coronary syndromes-no. (%) | 73(67.0) | 43(76.8) | 0.212 |
Stable angina-no. (%) | 36(33.0) | 13(23.2) | 0.212 |
Smoking history-no. (%) | 23 (21.1) | 15 (26.8) | 0.441 |
Drinking history-no. (%) | 47 (43.1) | 25 (44.6) | 1.000 |
History of present illness-no. (%) | |||
hypertension | 70 (64.2) | 38 (67.9) | 0.730 |
diabetes | 43 (39.4) | 22 (39.3) | 1.000 |
dyslipidemia | 62 (56.9) | 21 (37.5) | 0.024 |
cronic kidney disese | 8 (7.3) | 4 (7.1) | 1.000 |
hemodialysis | 2 (1.8) | 2 (3.6) | 0.605 |
Past peptic ulcer | 10 (9.2) | 2 (3.6) | 0.225 |
History of Medication-no. (%) | |||
H2 blocker | 1 (0.9) | 0 (0) | 1.000 |
NSAIDs | 4 (3.7) | 3 (5.4) | 0.690 |
anticoagulant | 12 (11.0) | 2 (3.6) | 0.143 |
antiplatelet drug other than DAPT | 5 (4.6) | 6 (10.7) | 0.186 |
Median duration of DAPT (day)-(IQR) | 341 (205–426) | 401 (333–535) | 0.004 |
Median duration of SAPT (day)-(IQR) | 314 (232–459) | 280 (137–337) | 0.019 |
SAPT using aspirin-no. (%) | 93(85.3) | 47(83.9) | 0.822 |